COMMUNIQUÉS West-GlobeNewswire

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU
18/07/2017
ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU ELB021 is a proprietary first-in-class monoclonal antibody targeting [...]
PHARMAGEST INTERACTIVE : acquisition majeure sur le marché de l'informatique hospitalière
18/07/2017
Villers-lès-Nancy, le 18 Juillet 2017 - 19h00 (CET) COMMUNIQUE DE PRESSE SYSTEME D'INFORMATION DE SANTE A L'HOPITAL ACQUISITION MAJEURE MALTA INFORMATIQUE, filiale du Groupe PHARMAGEST ( Euronext Paris #FR 0012882389 - [...]
SPINEWAY : Croissance confirmée sur le 1er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%)
18/07/2017
Communiqué de presse Ecully, le 18 juillet 2017 Croissance confirmée sur le 1 er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%) En Milliers d'euros 2016 2017* 1 er trimestre 1 109 3 110 2 ème trimestre 1 330 2 901 CA [...]
SPINEWAY : Confirmed growth Revenue for the first half of 2017: €6M (+146%)
18/07/2017
Press release Ecully, 18 July 2017 Confirmed growth Revenue for the first half of 2017: €6M (+146%) In thousands of euros 2016 2017* 1 st quarter 1 109 3 110 2 nd quarter 1 330 2 901 HY 1 revenue 2 439 6 010 * Figures [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
18/07/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
18/07/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
NICOX : Nombre de droits de vote au 17 juillet 2017
18/07/2017
Nicox SA Société anonyme au capital de 25 669 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 17 juillet 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]
NICOX : Number of voting rights as of July 17, 2017
18/07/2017
Number Nicox SA Société anonyme with a registered capital of € 25,669,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 17, 2017, MONTHLY PUBLICATION OF [...]
Summit Therapeutics plc : Result of AGM
18/07/2017
Summit Therapeutics plc ('Summit' or 'the Company') RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
18/07/2017
FIT Biotech Oy Company release July 18, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
18/07/2017
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and commercialization of a novel, potentially [...]
Shire plc : Notice of Results
18/07/2017
Shire to announce second quarter 2017 results Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017. Results press release will be [...]
Allergy Therapeutics: Trading Update
18/07/2017
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update 15% constant currency revenue growth Double-digit compound annual revenue growth over the past 18 years 18 July 2017 Allergy Therapeutics [...]
Midatech Pharma Plc: Trading Update and Notice of Results
18/07/2017
18 July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading Update and Notice of Results Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing [...]
uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
18/07/2017
Patent Covers Overlapping Rep78/52 Nucleotide Sequences for Robust, Large-Scale Production of AAV Constructs LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE [...]
Enzymatica recruits Chief Commercial Officer
18/07/2017
Press release Lund, 18 July 2017 Enzymatica recruits Chief Commercial Officer Enzymatica has recruited Claus Egstrand as its Chief Commercial Officer. Claus Egstrand's primary responsibility will be to develop [...]
CellaVision AB: Strong second quarter with growth and increased profitability
18/07/2017
Interim report January-June 2017 April 1-June 30, 2017 · Net sales increased by 20 % to SEK 78.7 million (65.7). · Organic growth for the quarter was 16% (27). · Operating profit increased by 29% to SEK 24.6 million (19 [...]
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18/07/2017
Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (USD 110 million) [...]
Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs
18/07/2017
Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec : Cosentyx (USD 490 millions, +90% [...]

Pages